Joana Briosa Neves
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Joana Briosa Neves has a total of 189 co-authors. Here are the top co-authors by number of shared publications:
- Maxine Gia Binh Tran
Division of Surgery and Interventional Sciences, University College London, London, UK
24 shared publications Faiz Mumtaz
Specialist Centre for Kidney Cancer Royal Free Hospital London UK
11 shared publicationsRavi Barod
Division of Surgery and Interventional Sciences University College London London UK
11 shared publicationsAxel Bex
Division of Surgery and Interventional Sciences University College London London UK
8 shared publicationsMichael Aitchison
Division of Surgery and Interventional Sciences University College London London UK
8 shared publicationsPrasad Patki
Department of Urology, Specialist Centre for Kidney Cancer Royal Free Hospital London UK
8 shared publications
Latest Publications
- Open Access
- 7 July 2025
- Published by Wiley in BJU International
- Vol. 136 (4) , 590-601
Natural history of treated and untreated renal oncocytoma: a systematic review and meta‐analysis
Introduction: Current guidelines recommend active surveillance, surgery, and ablation all as acceptable management strategies for renal oncocytoma, but there is growing concern about overtreatment. Our aim was to report the natural history of treated and untreated renal oncocytoma to inform clinical guidelines and shared decision‐making. Methods: A systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA). We systematically reviewed MEDLINE, EMBASE, CENTRAL and Clinicaltrials.gov from inception to 18 August 2023. Studies that reported outcomes during follow‐up for adult patients with treated and untreated histologically confirmed renal oncocytoma were included. The Joanna Briggs Institute tool was used to assess risk of bias for included studies. We present a narrative review and meta‐analysis. Results: There are no reports of distant metastases or disease‐related death for oncocytoma on active surveillance. Most oncocytomas on surveillance show limited growth (2 /year). A significant minority (14%) transition to active treatment, most often for tumour growth. Concordance between biopsy and surgical pathology was high (89%). Metastatic oncocytoma and disease‐related death after treatment was negligible, and exclusively in reports using historic diagnostic criteria defined prior to the World Health Organisation 1998 classification, and therefore likely including eosinophilic renal cell carcinomas. Conclusion: Active surveillance of oncocytoma is oncologically safe and allows patients to avoid the risk of morbidity and mortality with treatment. Imaging surveillance after active treatment can be safely omitted. The literature would benefit from prospective cohort studies of oncocytomas on surveillance, reporting surveillance protocols, and clinical outcomes including reasons for transition to active treatment.
- 7 July 2025
- Published by Wiley in BJU International
- Vol. 136 (4) , 590-601
Open AccessNatural history of treated and untreated renal oncocytoma: a systematic review and meta‐analysis
Introduction: Current guidelines recommend active surveillance, surgery, and ablation all as acceptable management strategies for renal oncocytoma, but there is growing concern about overtreatment. Our aim was to report the natural history of treated and untreated renal oncocytoma to inform clinical guidelines and shared decision‐making. Methods: A systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA). We systematically reviewed MEDLINE, EMBASE, CENTRAL and Clinicaltrials.gov from inception to 18 August 2023. Studies that reported outcomes during follow‐up for adult patients with treated and untreated histologically confirmed renal oncocytoma were included. The Joanna Briggs Institute tool was used to assess risk of bias for included studies. We present a narrative review and meta‐analysis. Results: There are no reports of distant metastases or disease‐related death for oncocytoma on active surveillance. Most oncocytomas on surveillance show limited growth (2 /year). A significant minority (14%) transition to active treatment, most often for tumour growth. Concordance between biopsy and surgical pathology was high (89%). Metastatic oncocytoma and disease‐related death after treatment was negligible, and exclusively in reports using historic diagnostic criteria defined prior to the World Health Organisation 1998 classification, and therefore likely including eosinophilic renal cell carcinomas. Conclusion: Active surveillance of oncocytoma is oncologically safe and allows patients to avoid the risk of morbidity and mortality with treatment. Imaging surveillance after active treatment can be safely omitted. The literature would benefit from prospective cohort studies of oncocytomas on surveillance, reporting surveillance protocols, and clinical outcomes including reasons for transition to active treatment.
- 30 December 2021
- Published by Wiley in BJU International
- Vol. 129 (1) , 28-31
‘Case of the Month’ from the Specialist Centre for Kidney Cancer, Royal Free London Hospital, UK: 99m Tc‐sestamibi SPECT‐CT to differentiate renal cell carcinoma from benign oncocytoma
- 30 December 2021
- Published by Wiley in BJU International
- Vol. 129 (1) , 28-31
‘Case of the Month’ from the Specialist Centre for Kidney Cancer, Royal Free London Hospital, UK: 99m Tc‐sestamibi SPECT‐CT to differentiate renal cell carcinoma from benign oncocytoma
- Open Access
- 28 May 2021
- Published by Wiley in BJU International
- Vol. 128 (6) , 722-727
Growth and renal function dynamics of renal oncocytomas in patients on active surveillance
Objectives: To study the natural history of renal oncocytomas and address indications for intervention by determining how growth is associated with renal function over time, the reasons for surgery and ablation, and disease‐specific survival. Patients and Methods: The study was conducted in a retrospective cohort of consecutive patients with renal oncocytoma on active surveillance reviewed at the Specialist Centre for Kidney Cancer at the Royal Free London NHS Foundation Trust (2012 to 2019). Comparison between groups was performed using Mann–Whitney U ‐tests and chi‐squared tests. A mixed‐effects model with a random intercept for patient was used to study the longitudinal association between tumour size and estimated glomerular filtration rate (eGFR). Results: Longitudinal data from 98 patients with 101 lesions were analysed. Most patients were men (68.3%) and the median (interquartile range [IQR]) age was 69 (13) years. The median (IQR) follow‐up was 29 (26) months. Most lesions were small renal masses, and 24% measured over 4 cm. Over half (64.4%) grew at a median (IQR) rate of 2 (4) mm per year. No association was observed between tumour size and eGFR over time ( P = 0.871). Nine lesions (8.9%) were subsequently treated. Two deaths were reported, neither were related to the diagnosis of renal oncocytoma. Conclusion: Natural history data from the largest active surveillance cohort of renal oncocytomas to date show that renal function does not seem to be negatively impacted by growing oncocytomas, and confirms clinical outcomes are excellent after a median follow‐up of over 2 years. Active surveillance should be considered the 'gold standard' management of renal oncocytomas up to 7cm.
- 28 May 2021
- Published by Wiley in BJU International
- Vol. 128 (6) , 722-727
Open AccessGrowth and renal function dynamics of renal oncocytomas in patients on active surveillance
Objectives: To study the natural history of renal oncocytomas and address indications for intervention by determining how growth is associated with renal function over time, the reasons for surgery and ablation, and disease‐specific survival. Patients and Methods: The study was conducted in a retrospective cohort of consecutive patients with renal oncocytoma on active surveillance reviewed at the Specialist Centre for Kidney Cancer at the Royal Free London NHS Foundation Trust (2012 to 2019). Comparison between groups was performed using Mann–Whitney U ‐tests and chi‐squared tests. A mixed‐effects model with a random intercept for patient was used to study the longitudinal association between tumour size and estimated glomerular filtration rate (eGFR). Results: Longitudinal data from 98 patients with 101 lesions were analysed. Most patients were men (68.3%) and the median (interquartile range [IQR]) age was 69 (13) years. The median (IQR) follow‐up was 29 (26) months. Most lesions were small renal masses, and 24% measured over 4 cm. Over half (64.4%) grew at a median (IQR) rate of 2 (4) mm per year. No association was observed between tumour size and eGFR over time ( P = 0.871). Nine lesions (8.9%) were subsequently treated. Two deaths were reported, neither were related to the diagnosis of renal oncocytoma. Conclusion: Natural history data from the largest active surveillance cohort of renal oncocytomas to date show that renal function does not seem to be negatively impacted by growing oncocytomas, and confirms clinical outcomes are excellent after a median follow‐up of over 2 years. Active surveillance should be considered the 'gold standard' management of renal oncocytomas up to 7cm.
- Open Access
- 26 May 2021
- Published by Wiley in BJU International
- Vol. 128 (6) , 685-687
Renal oncocytoma: landscape of diagnosis and management
Renal oncocytoma represents between 6-12% of T1 renal tumours in surgical series (1–2). Contemporary imaging cannot differentiate oncocytoma from malignant renal cell carcinoma (RCC). Uptake of renal tumour biopsy in clinical practice has been variable (3) and surgery with partial or radical nephrectomy is the first-line in the management of RCC (4,5). Therefore, many patients with renal masses undergo empirical surgery for presumed RCC with post-operative histologic diagnosis of benign oncocytoma.
- 26 May 2021
- Published by Wiley in BJU International
- Vol. 128 (6) , 685-687
Open AccessRenal oncocytoma: landscape of diagnosis and management
Renal oncocytoma represents between 6-12% of T1 renal tumours in surgical series (1–2). Contemporary imaging cannot differentiate oncocytoma from malignant renal cell carcinoma (RCC). Uptake of renal tumour biopsy in clinical practice has been variable (3) and surgery with partial or radical nephrectomy is the first-line in the management of RCC (4,5). Therefore, many patients with renal masses undergo empirical surgery for presumed RCC with post-operative histologic diagnosis of benign oncocytoma.
- Open Access
- 8 May 2021
- Published by Wiley in BJU International
- Vol. 128 (6) , 752-758
Impact of the first surge of the COVID‐19 pandemic on a tertiary referral centre for kidney cancer
Objective: To analyse the impact of the COVID‐19 pandemic on a centralized specialist kidney cancer care pathway. Materials and Methods: We conducted a retrospective analysis of patient and pathway characteristics including prioritization strategies at the Specialist Centre for Kidney Cancer located at the Royal Free London NHS Foundation Trust (RFH) before and during the surge of COVID‐19. Results: On 18 March 2020 all elective surgery was halted at RFH to redeploy resources and staff for the COVID‐19 surge. Prioritizing of patients according to European Association of Urology guidance was introduced. Clinics and the specialist multidisciplinary team (SMDT) meetings were maintained with physical distancing, kidney surgery was moved to a COVID‐protected site, and infection prevention measurements were enforced. During the 7 weeks of lockdown (23 March to 10 May 2020), 234 cases were discussed at the SMDT meetings, 53% compared to the 446 cases discussed in the 7 weeks pre‐lockdown. The reduction in referrals was more pronounced for small and asymptomatic renal masses. Of 62 low‐priority cancer patients, 27 (43.5%) were deferred. Only one (4%) COVID‐19 infection occurred postoperatively, and the patient made a full recovery. No increase in clinical or pathological upstaging could be detected in patients who underwent deferred surgery compared to pre‐COVID practice. Conclusion: The first surge of the COVID‐19 pandemic severely impacted diagnosis, referral and treatment of kidney cancer at a tertiary referral centre. With a policy of prioritization and COVID‐protected pathways, capacity for time‐sensitive oncological interventions was maintained and no immediate clinical harm was observed.
- 8 May 2021
- Published by Wiley in BJU International
- Vol. 128 (6) , 752-758
Open AccessImpact of the first surge of the COVID‐19 pandemic on a tertiary referral centre for kidney cancer
Objective: To analyse the impact of the COVID‐19 pandemic on a centralized specialist kidney cancer care pathway. Materials and Methods: We conducted a retrospective analysis of patient and pathway characteristics including prioritization strategies at the Specialist Centre for Kidney Cancer located at the Royal Free London NHS Foundation Trust (RFH) before and during the surge of COVID‐19. Results: On 18 March 2020 all elective surgery was halted at RFH to redeploy resources and staff for the COVID‐19 surge. Prioritizing of patients according to European Association of Urology guidance was introduced. Clinics and the specialist multidisciplinary team (SMDT) meetings were maintained with physical distancing, kidney surgery was moved to a COVID‐protected site, and infection prevention measurements were enforced. During the 7 weeks of lockdown (23 March to 10 May 2020), 234 cases were discussed at the SMDT meetings, 53% compared to the 446 cases discussed in the 7 weeks pre‐lockdown. The reduction in referrals was more pronounced for small and asymptomatic renal masses. Of 62 low‐priority cancer patients, 27 (43.5%) were deferred. Only one (4%) COVID‐19 infection occurred postoperatively, and the patient made a full recovery. No increase in clinical or pathological upstaging could be detected in patients who underwent deferred surgery compared to pre‐COVID practice. Conclusion: The first surge of the COVID‐19 pandemic severely impacted diagnosis, referral and treatment of kidney cancer at a tertiary referral centre. With a policy of prioritization and COVID‐protected pathways, capacity for time‐sensitive oncological interventions was maintained and no immediate clinical harm was observed.
- Open Access
- 25 April 2021
- Published by Cambridge Medicine Journal
- p. 7
European Association of Urology COVID intermediate prioritisation group is poorly predictive of pathological high- risk among patients with renal tumours
Introduction The purpose of prioritisation is to minimise harm while safeguarding access to health care in times of reduced resources. The EAU Guideline Office Rapid Reaction Group (GORRG) issued priority recommendations during the COVID-19 pandemic. We evaluated if the clinical prioritisation for suspected renal cell carcinoma (RCC) planned for surgery matched final pathological risk. Methods From 23 March 2020 until 10 October 2020, patients with suspected RCC were prioritised according to GORGG recommendations. To increase statistical power, GORGG prioritisation was also retrospectively assigned to pre-lockdown RCC surgical cases. The priority group was assessed according to GORGG guidelines, and postoperative risk was assessed according to 2003 Leibovich scores. We evaluated concordance between GORGG prioritisation and post-operative risk, and if stratification could be further improved by subgrouping of size. Results 351 patients with suspected RCC were prioritised and underwent surgery. The intermediate priority group showed poor concordance, with 25.7% and 16.4% being pathological low and high risk, respectively. The low priority group harboured 14.9% intermediate and 1.06% high risk RCC. Within the EAU intermediate group, 34.2% of cT1b tumours were low risk, and 32.3% of cT2a tumours high risk. Analysing at 1 cm increments, 45.1% of 4-5cm tumours were low risk. Conclusions The recommended prioritisation system can be error prone and should be prudently applied based on the centre’s needs. Particularly amongst the intermediate group, centres with clinical capacity should not defer intervention of cT2a tumours for longer than absolutely necessary and in severely limited resources may consider intermediate priority tumours < 5cm as low priority.
- 25 April 2021
- Published by Cambridge Medicine Journal
- p. 7
Open AccessEuropean Association of Urology COVID intermediate prioritisation group is poorly predictive of pathological high- risk among patients with renal tumours
Introduction The purpose of prioritisation is to minimise harm while safeguarding access to health care in times of reduced resources. The EAU Guideline Office Rapid Reaction Group (GORRG) issued priority recommendations during the COVID-19 pandemic. We evaluated if the clinical prioritisation for suspected renal cell carcinoma (RCC) planned for surgery matched final pathological risk. Methods From 23 March 2020 until 10 October 2020, patients with suspected RCC were prioritised according to GORGG recommendations. To increase statistical power, GORGG prioritisation was also retrospectively assigned to pre-lockdown RCC surgical cases. The priority group was assessed according to GORGG guidelines, and postoperative risk was assessed according to 2003 Leibovich scores. We evaluated concordance between GORGG prioritisation and post-operative risk, and if stratification could be further improved by subgrouping of size. Results 351 patients with suspected RCC were prioritised and underwent surgery. The intermediate priority group showed poor concordance, with 25.7% and 16.4% being pathological low and high risk, respectively. The low priority group harboured 14.9% intermediate and 1.06% high risk RCC. Within the EAU intermediate group, 34.2% of cT1b tumours were low risk, and 32.3% of cT2a tumours high risk. Analysing at 1 cm increments, 45.1% of 4-5cm tumours were low risk. Conclusions The recommended prioritisation system can be error prone and should be prudently applied based on the centre’s needs. Particularly amongst the intermediate group, centres with clinical capacity should not defer intervention of cT2a tumours for longer than absolutely necessary and in severely limited resources may consider intermediate priority tumours < 5cm as low priority.
- 13 April 2021
- Published by Springer Nature in World Journal of Urology
- Vol. 39 (10) , 3823-3831
Pattern, timing and predictors of recurrence after surgical resection of chromophobe renal cell carcinoma
Purpose Currently there are no specific guidelines for the post-operative follow-up of chromophobe renal cell carcinoma (chRCC). We aimed to evaluate the pattern, location and timing of recurrence after surgery for non-metastatic chRCC and establish predictors of recurrence and cancer-specific death. Methods Retrospective analysis of consecutive surgically treated non-metastatic chRCC cases from the Royal Free London NHS Foundation Trust (UK, 2015–2019) and the international collaborative database RECUR (15 institutes, 2006–2011). Kaplan–Meier curves were plotted. The association between variables of interest and outcomes were analysed using univariate and multivariate Cox proportional hazards regression models with shared frailty for data source. Results 295 patients were identified. Median follow-up was 58 months. The five and ten-year recurrence-free survival rates were 94.3% and 89.2%. Seventeen patients (5.7%) developed recurrent disease, 13 (76.5%) with distant metastases. 54% of metastatic disease diagnoses involved a single organ, most commonly the bone. Early recurrence (< 24 months) was observed in 8 cases, all staged ≥ pT2b. 30 deaths occurred, of which 11 were attributed to chRCC. Sarcomatoid differentiation was rare (n = 4) but associated with recurrence and cancer-specific death on univariate analysis. On multivariate analysis, UICC/AJCC T-stage ≥ pT2b, presence of coagulative necrosis, and positive surgical margins were predictors of recurrence and cancer-specific death. Conclusion Recurrence and death after surgically resected chRCC are rare. For completely excised lesions ≤ pT2a without coagulative necrosis or sarcomatoid features, prognosis is excellent. These patients should be reassured and follow-up intensity curtailed.
- 13 April 2021
- Published by Springer Nature in World Journal of Urology
- Vol. 39 (10) , 3823-3831
Pattern, timing and predictors of recurrence after surgical resection of chromophobe renal cell carcinoma
Purpose Currently there are no specific guidelines for the post-operative follow-up of chromophobe renal cell carcinoma (chRCC). We aimed to evaluate the pattern, location and timing of recurrence after surgery for non-metastatic chRCC and establish predictors of recurrence and cancer-specific death. Methods Retrospective analysis of consecutive surgically treated non-metastatic chRCC cases from the Royal Free London NHS Foundation Trust (UK, 2015–2019) and the international collaborative database RECUR (15 institutes, 2006–2011). Kaplan–Meier curves were plotted. The association between variables of interest and outcomes were analysed using univariate and multivariate Cox proportional hazards regression models with shared frailty for data source. Results 295 patients were identified. Median follow-up was 58 months. The five and ten-year recurrence-free survival rates were 94.3% and 89.2%. Seventeen patients (5.7%) developed recurrent disease, 13 (76.5%) with distant metastases. 54% of metastatic disease diagnoses involved a single organ, most commonly the bone. Early recurrence (< 24 months) was observed in 8 cases, all staged ≥ pT2b. 30 deaths occurred, of which 11 were attributed to chRCC. Sarcomatoid differentiation was rare (n = 4) but associated with recurrence and cancer-specific death on univariate analysis. On multivariate analysis, UICC/AJCC T-stage ≥ pT2b, presence of coagulative necrosis, and positive surgical margins were predictors of recurrence and cancer-specific death. Conclusion Recurrence and death after surgically resected chRCC are rare. For completely excised lesions ≤ pT2a without coagulative necrosis or sarcomatoid features, prognosis is excellent. These patients should be reassured and follow-up intensity curtailed.
- 30 March 2021
- Published by SAGE Publications in Journal of Clinical Urology
- Vol. 15 (4) , 323-330
Clinical experience of using virtual 3D modelling for pre and intraoperative guidance during robotic-assisted partial nephrectomy
Objective: Surgical planning for robotic-assisted partial nephrectomy is widely performed using two-dimensional computed tomography images. It is unclear to what extent two-dimensional images fully simulate surgical anatomy and case complexity. To overcome these limitations, software has been developed to reconstruct three-dimensional models from computed tomography data. We present the results of a feasibility study, to explore the role and practicality of virtual three-dimensional modelling (by Innersight Labs) in the context of surgical utility for preoperative and intraoperative use, as well as improving patient involvement. Methods: A prospective study was conducted on patients undergoing robotic-assisted partial nephrectomy at our high volume kidney cancer centre. Approval from a research ethics committee was obtained. Patient demographics and tumour characteristics were collected. Surgical outcome measures were recorded. The value of the three-dimensional model to the surgeon and patient was assessed using a survey. The prospective cohort was compared against a retrospective cohort and cases were individually matched using RENAL (radius, exophytic/endophytic, nearness to collecting system or sinus, anterior/posterior, location relative to polar lines) scores. Results: This study included 22 patients. Three-dimensional modelling was found to be safe for this prospective cohort and resulted in good surgical outcome measures. The mean (standard deviation) console time was 158.6 (35) min and warm ischaemia time was 17.3 (6.3) min. The median (interquartile range) estimated blood loss was 125 (50–237.5) ml. Two procedures were converted to radical nephrectomy due to the risk of positive margins during resection. The median (interquartile range) length of stay was 2 (2–3) days. No postoperative complications were noted and all patients had negative surgical margins. Patients reported improved understanding of their procedure using the three-dimensional model. Conclusion: This study shows the potential benefit of three-dimensional modelling technology with positive uptake from surgeons and patients. Benefits are improved perception of vascular anatomy and resection approach, and procedure understanding by patients. A randomised controlled trial is needed to evaluate the technology further. Level of evidence: 2b
- 30 March 2021
- Published by SAGE Publications in Journal of Clinical Urology
- Vol. 15 (4) , 323-330
Clinical experience of using virtual 3D modelling for pre and intraoperative guidance during robotic-assisted partial nephrectomy
Objective: Surgical planning for robotic-assisted partial nephrectomy is widely performed using two-dimensional computed tomography images. It is unclear to what extent two-dimensional images fully simulate surgical anatomy and case complexity. To overcome these limitations, software has been developed to reconstruct three-dimensional models from computed tomography data. We present the results of a feasibility study, to explore the role and practicality of virtual three-dimensional modelling (by Innersight Labs) in the context of surgical utility for preoperative and intraoperative use, as well as improving patient involvement. Methods: A prospective study was conducted on patients undergoing robotic-assisted partial nephrectomy at our high volume kidney cancer centre. Approval from a research ethics committee was obtained. Patient demographics and tumour characteristics were collected. Surgical outcome measures were recorded. The value of the three-dimensional model to the surgeon and patient was assessed using a survey. The prospective cohort was compared against a retrospective cohort and cases were individually matched using RENAL (radius, exophytic/endophytic, nearness to collecting system or sinus, anterior/posterior, location relative to polar lines) scores. Results: This study included 22 patients. Three-dimensional modelling was found to be safe for this prospective cohort and resulted in good surgical outcome measures. The mean (standard deviation) console time was 158.6 (35) min and warm ischaemia time was 17.3 (6.3) min. The median (interquartile range) estimated blood loss was 125 (50–237.5) ml. Two procedures were converted to radical nephrectomy due to the risk of positive margins during resection. The median (interquartile range) length of stay was 2 (2–3) days. No postoperative complications were noted and all patients had negative surgical margins. Patients reported improved understanding of their procedure using the three-dimensional model. Conclusion: This study shows the potential benefit of three-dimensional modelling technology with positive uptake from surgeons and patients. Benefits are improved perception of vascular anatomy and resection approach, and procedure understanding by patients. A randomised controlled trial is needed to evaluate the technology further. Level of evidence: 2b
- 9 July 2020
- Published by Springer Nature in World Journal of Urology
- Vol. 39 (10) , 4003-4004
Oncocytoma: risk of promoting unnecessary surgery
- 9 July 2020
- Published by Springer Nature in World Journal of Urology
- Vol. 39 (10) , 4003-4004
Oncocytoma: risk of promoting unnecessary surgery